Role of Growth Factors in Diabetic Kidney Disease

Abstract

Diabetic nephropathy (DN) is one of the major microvascular complications of diabetes and one of the leading causes of death among patients with diabetes. DN is characterized by excessive amassing of extracellular matrix with thickening of glomerular and tubular basement membranes and increased amount of mesangial matrix, which ultimately progress to glomerulosclerosis and tubulo-interstitial fibrosis. The high intracellular glucose environment due to an increased cellular uptake of glucose activates several pathways related to the production of advanced glycation endproducts, cytokines, chemokines, growth factors, reactive oxidative species, which are all final mediators of renal damage in human and experimental diabetes. Several growth factors have been implicated in the pathogenesis of DN, through complex intra-renal systems. Transforming growth factor beta, connective tissue growth factor, vascular endothelial growth factor, growth hormone and insulin-like growth factors are among those best known and investigated. There are also data, even though limited, on the involvement of other two growth factors, epidermal growth factor and platelet derived growth factor, in the pathogenesis of DN. These growth factors, which are generally expressed in the normal kidney and whose levels increase in relation to diabetes, have been implicated in the control of renal matrix composition, cell hypertrophy, proliferation and survival, modulation of cells of the immune system, and enzymes involved in glucose metabolism. The development of specific inhibitors of growth factors has provided further evidence for the involvement of growth factors in the development and progression of DN and further studies might help in developing new potential therapeutical interventions.

diabetic nephropathy - type 1 diabetes mellitus - growth factors

References

• 1 World Health Organization. . Diabetes: World Health Organization Fact Sheet. Geneva: World Health Organization 2006: 1-2 (no. 312)
• 2 Russel TA. Diabetic Nephropathy in patients with type 1 diabetes mellitus.  Nephrol Nurs J. 2006;  33 15-28
• 3 , US Renal Data system: annual Data Report 2005. Available: http://www.usrds.org/adr.htm
• 4 Van Dijk PC, Jager KJ, Stengel B, Gronhagen-Riska C, Feest TG, Briggs JD. Renal replacement therapy for diabetic end-stage renal disease: data from 10 registries in Europe (1991–2000).  Kidney Int. 2005;  67 1489-1499
• 5 Rossing P. Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005.  Diabetologia. 2006;  49 11-19
• 6 Bogdanović R. Diabetic nephropathy in children and adolescents.  Pediatr Nephrol. 2008;  23 507-255
• 7 Cooper ME. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy.  Diabetologia. 2001;  44 1957-1972
• 8 Osterby R. Glomerular structural changes in type 1 (insulin-dependent) diabetes mellitus: causes, consequences, and prevention.  Diabetologia. 1992;  35 803-812
• 9 Chiarelli F, Santilli F, Mohn A. Role of growth factors in the development of diabetic complications.  Horm Res. 2000;  53 53-67
• 10 Navarro JF, Mora-Fernandez. The role of TNF-α nephropathy: Pathogenic and therapeutic implications.  Cytokine Growth Factor Rev. 2006;  17 441-450
• 11 Reeves WB, Andreoli TE. Transforming Growth Factor-β contributes to progressive diabetic nephropathy.  Proc Natl Acad Sci U S A. 2000;  97 7667-7669
• 12 Tsuchida KI, Cronin B, Sharma K. Novel aspects of transforming growth factor-beta in diabetic kidney disease.  Nephron. 2002;  92 7-21
• 13 Reddy AS. Diabetic Nephropathy: Theory & practise. East Hanover, NJ: College Book Publishers. L.L.C. 2004: 563
• 14 Monkawa T, Hiromura K, Wolf G, Shankland SJ. The hypertrophic effect of transforming growth factor-beta is reduced in the absence of cyclin-dependent kinase-inhibitors p21 and p27.  J Am Soc Nephrol. 2002;  13 1172-1178
• 15 Chen S, Jim B, Ziyadeh FN. Diabetic nephropathy and transforming Growth Factor-β: Transforming our view of glomerulosclerosis and fibrosis build-up.  Semin Nephol. 2003;  23 532-543
• 16 Ziyadeh FN, Sharma K. Role of transforming growth factor-beta in diabetic glomerulosclerosis and renal hypertrophy.  Kidney Int. 1995;  51 S34-S36
• 17 Yamagishi SI, Inagaki Y, Okamoto T. Advanced glycation end products inhibit de novo protein synthesis and induce TGF-beta overexpression in proximal tubular cells.  Kidney Int. 2003;  63 464-473
• 18 Kang MJ, Ingram A, Ly H, Thai K, Scholey JW. Effects of diabetes and hypertension on glomerular transforming growth factor-beta receptor expression.  Kidney Int. 2000;  58 1677-1685
• 19 Wang S, Skorczewski J, Feng X, Mei L, Murphy-Ullrich JE. Glucose up-regulates thrombospondin 1 gene transcription and transforming growth factor-beta activity through antagonism of cGMP-dependent protein kinase repression via upstream stimulatory factor 2.  J Biol Chem. 2004;  279 34311-34322
• 20 Lawrence DA. Transforming growth factor-beta: a general review.  Eur Cytokine Netw. 1996;  7 363-374
• 21 Ribeiro SM, Poczatek M, Schultz-Cherry S, Villain M, Murphy-Ullrich JE. The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-beta.  J Biol Chem. 1999;  274 13586-13593
• 22 Yevdokimova N, Wahab NA, Mason RM. Thrombospondin-1 is the key activator of TGF-beta1 in human mesangial cells exposed to high glucose.  J Am Soc Nephrol. 2001;  12 703-712
• 23 Yung S, Lee CY, Zhang Q, Lau SK, Tsang RC, Chan TM. Elevated glucose induction of thrombospondin-1 up-regulates fibronectin synthesis in proximal renal tubular epithelial cells through TGF-beta1 dependent and TGF-beta1 independent pathways.  Nephrol Dial Transplant. 2006;  21 1504-1513
• 24 Daniel C, Schaub K, Amann K, Lawler J, Hugo C. Thrombospondin-1 is an endogenous activator of TGF-beta in experimental diabetic nephropathy in vivo.  Diabetes. 2007;  56 2982-2989
• 25 Reeves WB, Andreoli TE. Transforming Growth Factor-β contributes to progressive diabetic nephropathy.  Proc Natl Acad Sci USA. 2000;  97 7667-7669
• 26 Sharma K, Eltayeb BO, McGowan TA, Dunn SR, Alzahabi B, Rohde R, Ziyadeh FN, Lewis EJ. Captopril-induced reduction of serum levels of transforming growth factor-beta1 correlates with long-term renoprotection in insulin-dependent diabetic patients.  Am J Kidney Dis. 1999;  34 818-823
• 27 Ohtomo S, Izuhara Y, Takizawa S, Yamada N, Kakuta T, van Ypersele de Strihou C, Miyata T. Thiazolidinediones provide better renoprotection that insulin in a obese, hypertensive type II diabetic rat model.  Kidney Int. 2007;  72 1512-1519
• 28 Lang F, Klingel K, Wagner CA, Stegen C, Warntges S, Friedrich B, Lanzendorfer M, Melzig J, Moschen I, Steuer S, Waldegger S, Sauter M, Paulmichl M, Gerke V, Risler T, Gamba G, Capasso G, Kandolf R, Hebert SC, Massry SG, Broër S. Deranged transcriptional regulation of cell-volume-sensitive kinase hSGK in diabetic nephropathy.  Proc Natl Acad Sci USA. 2000;  97 8157-8162
• 29 Korpinem E, Teppo AM, Hukkanem L, Akerblom HK, Gronhagen-Riska C, Vaarala O. Urinary Transforming Growth Factor-β1 and 1-Microglobulin Children and Adolescents With Type 1 Diabetes.  Diabetes Care. 2000;  23 664-668
• 30 Han DC, Isono M, Hoffman BB, Ziyadeh FN. High glucose stimulates proliferation and collagen type 1 synthesis in renal cortical fibroblasts: mediation by autocrine activation of TGF-β1.  J Am Soc Nephrol. 1999;  10 1891-1899
• 31 Sharma K, Jin Y, Guo J, Ziyadeh FN. Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice.  Diabetes. 1996;  45 522-530
• 32 Kulkarni AB, Ward JM, Yaswen L, Mackall CL, Bauer SR, Huh CG, Gress RE, Karlsson S. Transforming growth factor-beta 1 null mice.  An animal model for inflammatory disorders. Am J Pathol. 1995;  146 264-275
• 33 Wang S, Hirscheberg R. BMP-7 antagonizes TGF-beta-dependent fibrogenesis in mesangial cells.  Am J Physiol Renal Pysiol. 2003;  284 1006-1013
• 34 Guha M, Xu ZG, Tung D, Lanting L, Natarajan R. Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes.  FASEB J. 2007;  21 3355-3368
• 35 Riser BL, Denichilo M, Cortes P, Baker C, Grondin JM, Yee J, Narins RG. Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis.  J Am Soc Nephrol. 2000;  11 25-38
• 36 Sakharova OV, Taal MW, Brenner BM. Pathogenesis of diabetic nephropathy: focus on transforming growth factor-beta and connective tissue growth factor.  Curr Opin Nephrol Hypertens. 2001;  10 727-738
• 37 Wahab NA, Yevdokimova N, Weston BS, Roberts T, Li XJ, Brinkman H, Mason RM. Role of connective tissue growth factor in the pathogenesis of diabetic nephropathy.  Biochem J. 2001;  359 77-87
• 38 Hishikawa K, Oemar BS, Nakaki T. Static pressure regulates connective tissue growth factor expression in human mesangial cells.  J Biol Chem. 2001;  276 16797-16803
• 39 Twigg SM, Chen MM, Joly AH, Chakrapani SD, Tsubaki J, Kim HS, Oh Y, Rosenfeld RG. Advanced glycosylation end products up-regulate connective tissue growth factor (insulin-like growth factor-binding protein-related protein 2) in human fibroblasts: a potential mechanism for expansion of extracellular matrix in diabetes mellitus.  Endocrinology. 2001;  142 1760-1769
• 40 Wang S, Denichilo M, Brubaker C, Hirschberg R. Connective tissue growth factor in tubulointerstitial injury of diabetic nephropathy.  Kidney Int. 2001;  60 96-105
• 41 Burns W, Twigg S, Forbes J, Pete J, Tikellis C, Thallas-Bonke V, Thomas MC, Cooper ME, Kantharidis P. Connective Tissue Growth Factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease.  J Am Soc Nephrol. 2006;  17 2484-2494
• 42 Kobayashi T, Inoue T, Okada H, Kikuta T, Kanno Y, Nishida T, Takigawa M, Sugaya T, Suzuki H. Connective tissue growth factor mediates the profibrotic effects of transforming growth factor-β produced by tubular epithelial cells in response to high glucose.  Clin Exp Nephrol. 2005;  9 114-121
• 43 Roestenberg P, van Nieuwenhoven FA, Joles JA, Trischberger C, Martens PP, Oliver N, Aten J, Hoppener JW, Goldschmeding R. Temporal expression profile and distribution pattern indicate a role of connective tissue growth factor (CTGF/CCN-2) in diabetic nephropathy in mice.  Am J Physiol Renal Physiol. 2006;  290 F1344-F1354
• 44 Gilbert RE, Akdeniz A, Weitz S, Usinger WR, Molineaux C, Jones SE, Langham RG, jerums G. Urinary connective tissue growth factor excretion in patients with type 1 diabetes and nephropathy.  Diabetes Care. 2003;  26 2632-2636
• 45 Riser BL, Cortes P, deNichilo M, Deshmukh PV, Chahal PS, Mohammed AK, Yee J, Kahkonem D. Urinary CCN2 as a possible predictor of diabetic nephropathy: preliminary report.  Kidney Int. 2003;  64 451-458
• 46 Nguyen TQ, Tarnow L, Jorsal A, Oliver N, Roestenberg P, Ito Y, Parving HH, Rossing P, van Nieuwenhoven FA, Goldschmeding R. Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortality in type 1 diabetic nephropathy.  Diabetes Care. 2008;  31 1177-1182
• 47 Nguyen TQ, Tarnow L, Andersen S, Hovind P, Parving HH, Goldschmeding R, van nieuwenhoven FA. Urinary connective tissue growth factor excretion correlates with clinical markers of renal disease in a large population of type 1 diabetic patients with diabetic nephropathy.  Diabetes Care. 2006;  29 83-88
• 48 Guha M, Xu ZG, Tung D, Lanting L, Natarajan R. Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes.  FASEB J. 2007;  21 3355-3368
• 49 Khamaisi M, Schrijvers BF, DeVriese AS, Raz I, Flyvbjerg A. The emerging role of VEGF in diabetic kidney disease.  Nephrol Dial Transplant. 2003;  18 1427-1430
• 50 De Vriese AS, Tilton RG, Elger M, Stephan C, Kriz W, Lameire NH. Antibodies against Vascular Endothelial Growth Factor Improve Early Renal Dysfunction in Experimental Diabetes.  J Am Soc Nephrol. 2001;  12 993-1000
• 51 Chiarelli F, Spagnoli A, Basciani F, Tumini S, Mezzetti A, Cipollone F, Cuccurullo F, Morgese G, Verrotti A. Vascular endothelial growth factor (VEGF) in children, adolescents and young adults with Type 1 diabetes mellitus: relation to glycaemic control and microvascular complications.  Diabetes. 2000;  17 650-656
• 52 Cooper ME, Vranes D, Youssef S, Stacker SA, Cox AJ, Rizkalla B, Casley DJ, Bach LA, Kelly DJ, Gilbert RE. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes.  Diabetes. 1999;  48 2229-2239
• 53 Chiarelli F, de Martino M, Mezzetti A, Catino M, Morgese G, Cuccurullo F, Verrotti A. Advanced glycation end products in children and adolescents with diabetes: relation to glycemic control and early microvascular complications.  J Pediatr. 1999;  134 486-491
• 54 Santilli F, Spagnoli A, Mohn A, Tumini S, Verrotti A, Cipollone F, Mezzetti A, Chiarelli F. Increased vascular endothelial growth factor serum concentrations may help to identify patients with onset of type 1 diabetes during childhood at risk for developing persistent microalbuminuria.  J Clin Endocrinol Metab. 2001;  86 3871-3876
• 55 Senthil D, Choudhury GG, McLaurin C, Kasinath BB. Vascular endothelial growth factor induces protein synthesis in renal epithelial cells: A potential role in diabetic nephropathy.  Kidney Int. 2003;  64 468-479
• 56 Ziche M, Morbidelli L, Choudhuri R, Zhang HT, Donnini S, Granger HJ, Bicknell R. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis.  J Clin Invest. 1997;  99 2625-2634
• 57 Hood JD, Meininger CJ, Ziche M, Granger HJ. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells.  Am J Physiol. 1998;  274 H1054-H1058
• 58 Iglesias de la Cruz MC, Ziyadeh FN, Isono M, Kouahou M, Han DC, Kalluri R, Mundel P, Chen S. Effects of high glucose and TGF-β on the expression of collagen IV and vascular endothelial growth factor in mouse podocytes.  Kidney Int. 2002;  62 901-913
• 59 Iozzo RV. Heparan sulphate proteoglycans: intricate molecules with intriguing functions.  J Clin Invest. 2001;  108 165-167
• 60 Gabbai FB, Blantz RC. Role of nitric oxide in renal hemodynamics.  Semin Nephrol. 1999;  19 242-250
• 61 Baelde HJ, Eikmans M, Lappin DWP, Doran PP, Hohenadel D, Brinkkoetter P-T, van der Woude FJ, Waldherr R, Rabelink TJ, de Heer E, Bruijn JA. Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss.  Kidney Int. 2007;  71 637-645
• 62 Dalla VM, Masiero A, Roiter AM. Is podocyte injury relevant in diabetic nephropathy? Studies in patients with type 2 diabetes.  Diabetes. 2003;  52 1031-1035
• 63 Susztak K, Raff AC, Schiffer M, Bottinger EP. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy.  Diabetes. 2006;  55 225-233
• 64 Coward RJM, Welsh GI, Yang J, Tasman C, Lennon R, Koziell A, Satchell S, Holman GD, Kerjaschki D, Tavaré JM, Mathieson PW, Saleem MA. The human glomerular podocyte is a novel target for insulin action.  Diabetes. 2005;  54 3095-3102
• 65 Durvasula RV, Shankland SJ. Mechanical strain increases SPARC levels in podocytes implications for glomerulosclerosis.  Am J Physiol Renal Physiol. 2005;  289 E577-F584
• 66 Cooper ME, Thomas MC. Interactions between growth factors in the kidney: implications for progressive renal injury.  Kidney Int. 2003;  63 1584-1585
• 67 Dunger DB, Acerini CL. IGF-I and diabetes in adolescence.  Diabetes Metab. 1998;  24 101-107
• 68 Dunger DB, Cheetham TD. Growth hormone insulin-like growth factor I axis in insulin-dependent diabetes mellitus.  Horm Res. 1996;  46 2-6
• 69 Vasylyeva TL, Ferry RJ. Novel roles of the IGF-IGFBP axis in etiopathophysiology of diabetic nephropathy.  Diabetes Res Clin Pract. 2007;  76 177-186
• 70 Rabkin R, Schaefer F. New concepts: growth hormone, insulin-like growth factor-I and the kidney.  Growth Horm IGF Res. 2004;  14 270-276
• 71 Moller J. Effects of growth hormone on fluid homeostasis. Clinical and experimental aspects.  Growth Horm IGF Res. 2003;  13 55-74
• 72 Ferry Jr RJ, Cohen P. The insulin-like growth factor axis in pediatrics.  Clin Pediatr Endocrinol. 1999;  8 1-10
• 73 Han HJ, Kang CW, Park SH. Tissue-specific regulation of insulin-like growth factors and insulin- like growth factors binding proteins in male diabetic rats in vivo and in vitro.  Clin Exp Pharmacol Physiol. 2006;  33 1172-1179
• 74 Wędrychowicz A, Dziatkowiak H, Nazim J, Sztefko K. Insulin-Like Growth Factor-1 and Its Binding Proteins, IGFBP-1 and IGFBP-3, in Adolescents with Type-1 Diabetes mellitus and Microalbuminuria.  Horm Res. 2005;  63 245-251
• 75 Reiter EO, Rosenfeld RG. IGFs and its binding proteins. In: Greenspan F, Strewler G, ed. Basic and Clinical Endocrinology. East Norwalk, CT: Appleton & Lange 1997: 1437-1453
• 76 Cummings EA, Sochett EB, Dekker MG, Lawson ML, Daneman D. Contribution of growth hormone and IGF-I to early diabetic nephropathy in type 1 diabetes.  Diabetes. 1998;  47 1341-1346
• 77 Amin R, Schultz C, Ong K, Frystyk J, Dalton RN, Perrv E, Orskov H, Dunger DB. Low IGF-I and elevated testosterone during puberty in subjects with type 1 diabetes developing microalbuminuria in comparison to normoalbuminuric control subjects.  Diabetes Care. 2003;  26 1456-1461
• 78 Bereket A, Lang CH, Wilson TA. Alterations in the growth hormone-insulin-like growth factor axis in insulin dependent diabetes mellitus.  Horm Metab Res. 1999;  31 172-181
• 79 Niedzwiedzka A, Dziatkowiak H, Sztefko K. Insulin-like growth factor I (IGF-I) and its binding proteins 1 and 3 in children and adolescents with IDDM.  Horm Res. 1999;  5l ((Suppl 2)) 95
• 80 Shinada M, Akdeniz A, Panagiotopoulos S, Jerums G, Bach LA. Proteolysis of insulin-like growth factor-binding protein-3 is increased in urine from patients with diabetic nephropathy.  J Clin Endocrinol Metab. 2000;  85 1163-1169
• 81 Vasylyeva TL, Chen X, Ferry RJ. Insulin-like growth factor-binding protein-3 mediates cytokine-induced mesangial cell apoptosis.  Growth Horm IGF Res. 2005;  15 207-214
• 82 Landau D, Segey Y, Afargan M. A novel somatostatin analogue prevents early renal complications in the nonobese diabetic mouse.  Kidney Int. 2001;  60 505-512
• 83 Flyvbjerg A. Potential use of growth hormone receptor antagonist in the treatment of diabetic kidney disease.  Growth Horm IGF Res. 2001;  11 S115-S119
• 84 Segev Y, Landau D, Rasch R, Flyvbjerg A, Phillip M. Growth hormone receptor antagonism prevents early renal changes in nonobese diabetic mice.  J Am Soc Nephrol. 1999;  10 2374-2381
• 85 Abboud HE. Role of platelet-derived growth factor in renal injury.  Annu Rev Physiol. 1995;  57 297-309
• 86 Fagerudd JA, Groop PH, Honkanen E, Teppo AM, Gronhagen-Riska C. Urinary excretion of TGF-beta 1, PDGF-BB and fibronectin in insulin-dependent diabetes mellitus patients.  Kidney Int Suppl. 1997;  63 S195-S197
• 87 Nakagawa H, Sasahara M, Haneda M, Koya D, Hazama F, Kikkawa R. Immunohistochemical characterization of glomerular PDGF B-chain and PDGF beta-receptor expression in diabetic rats.  Diabetes Res Clin Pract. 2000;  48 87-98
• 88 Soyombo AA, DiCorleto PE. Stable expression of human platelet-derived growth factor B chain by bovine aortic endothelial cells. Matrix association and selective proteolytic cleavage by thrombin.  J Biol Chem. 1994;  269 17734-17740
• 89 Langham RG, Kelly DJ, Maguire J, Dowling JP, Gilbert RE, Thomson NM. Over-expression of platelet-derived growth factor in human diabetic nephropathy.  Nephrol Dial Transplant. 2003;  18 1392-1396
• 90 Uehara G, Suzuki D, Toyoda M, Umezono T, Sakai H. Glomerular expression of platelet-derived growth factor (PDGF)-A,-B chain and PDGF receptor-alpha, -beta in human diabetic nephropathy.  Clin Exp Nephrol. 2004;  8 36-42
• 91 Eitner F, Bücher E, van Roeyen C, Kunter U, Rong S, Seikrit C, Villa L, Boor P, Fredriksson L, Bäckström G, Eriksson U, Ostman A, Floege J, Ostendorf T. PDGF-C is a proinflammatory cytokine that mediates renal interstitial fibrosis.  J Am Soc Nephrol. 2008;  19 281-289
• 92 Gilbert RE, Cox A, MacNally PG, Wu LL, Dziadek M, Cooper ME, Jerums G. Increased epidermal growth factor in experimental diabetes related kidney growth in rats.  Diabetologia. 1997;  40 778-785
• 93 Kanda S, Igawa T, Sakai H, Nomata K, Kanetake H, Saito Y. Anti-epidermal growth factor antibody inhibits compensatory renal hyperplasia but not hypertrophy after unilateral nephrectomy in mice.  Biochem Biophys Res Commun. 1992;  187 1015-1021
• 94 Stevens VA, Saad S, Chen XM, Pollock CA. The interdependence of EGF-R and SGK-1 in fibronectin expression in primary kidney cortical fibroblast cells.  Intern J Biochem Cell Biol. 2007;  39 1047-1054
• 95 Feng Y, Wang Q, Wang Y, Yard B, Lang F. SGK1 mediated fibronectin formation in diabetic nephropathy.  Cell Physiol Biochem. 2005;  16 237-244
• 96 Yun CC. Concerted roles of SGK1 and the Na⁺-H⁺ exchanger regulatory factor 2 (NHERF2) in regulation of NHE3.  Cell Physiol Biochem. 2003;  13 29-40
• 97 Warntges S, Grone HJ, Capasso G. Cell volume regulatory mechanisms in progression of renal disease.  J Nephrol. 2001;  14 319-326
• 98 Wassef L, Kelly DJ, Gilbert RE. Epidermal growth factor receptor inhibition attenuates early kidney enlargement in experimental diabetes.  Kidney Int. 2004;  66 1805-1814

Correspondence